SCHEMBL15766965

SCHEMBL15766965

CCCCCC([C]=O)C#N

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
MAPT P10636 1/20 0.38
OPRM1 P35372 1/20 0.36
FDPS P14324 4/20 0.35
GPR84 Q9NQS5 5/20 0.34
CA1 P00915 2/20 0.34
FFAR1 O14842 1/20 0.34
TP53 P04637 1/20 0.33
LAP3 P28838 1/20 0.33
LMNA P02545 1/20 0.33
LCK P06239 1/20 0.33
PPARD Q03181 1/20 0.33
ZDHHC20 Q5W0Z9 1/20 0.33
ZDHHC2 Q9UIJ5 1/20 0.33
ADH1B P00325 1/20 0.32
ADH1C P00326 1/20 0.32
ADH1A P07327 1/20 0.32
ADH4 P08319 1/20 0.32
ADH7 P40394 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11396254 0.98 MAPT (0.41) TSHRMAPTFDPSGPR84FFAR1
SCHEMBL1019048 0.93
SCHEMBL366803 0.85 MAPT (0.43) TSHRMAPTOPRM1FDPSGPR84
SCHEMBL319320 0.85 TSHR (0.46) TSHROPRM1FDPSGPR84LMNA
SCHEMBL3979603 0.83 TSHR (0.43) TSHROPRM1FDPSGPR84LMNA
SCHEMBL3978555 0.83 TSHR (0.43) TSHROPRM1FDPSGPR84LMNA
SCHEMBL28129612 0.83 TSHR (0.43) TSHROPRM1FDPSGPR84LMNA
SCHEMBL486866 0.83 TSHR (0.43) TSHROPRM1FDPSGPR84LMNA
SCHEMBL27634401 0.83 TSHR (0.43) TSHROPRM1FDPSGPR84LMNA
SCHEMBL8044861 0.83 TSHR (0.43) TSHROPRM1FDPSGPR84LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040516-B2 Uracil derivative and use thereof for medical purposes SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-05-26 US disclosed
US-20140179670-A1 URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-06-26 US disclosed
EP-2740728-A1 URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Dainippon Sumitomo Pharma Co., Ltd. (JP) 2014-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179670-A1 URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES URB2, ELANE, NUDT1 TSHR 3016/4885MAPT 4663/4885OPRM1 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.